US Stock MarketDetailed Quotes

EVAX Evaxion Biotech

Watchlist
  • 3.000
  • -0.060-1.96%
Close Sep 13 16:00 ET
  • 3.000
  • 0.0000.00%
Post 20:01 ET
16.73MMarket Cap-666P/E (TTM)
Full Hours
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Trytosaveabit
    Trytosaveabit
    Sep 9 07:06
    More
    $Evaxion Biotech (EVAX.US)$ Evaxion Reports 69% Overall Response Rate in Its Phase 2 Trial on Lead Cancer Vaccine Candidate Evx-01
    Jaguar8
    Jaguar8
    Sep 9 07:05
    NEWS
    $Evaxion Biotech (EVAX.US)$
    Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine candidate EVX-01
    • Topline data from a one-year interim analysis of the ongoing phase 2 trial show that 11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate
    • 15 out of the 16 patients had reduction of their tumors (target lesions)
    • The complete one-year dataset will be presented at the ESMO congress this week and discussed at a webinar...
    Jaguar8
    Jaguar8
    Jul 16 08:44
    NEWS
    $Evaxion Biotech (EVAX.US)$
    Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference
    Evaxion Biotech A/S (NASDAQ: EVAX) has unveiled improved performance of its key AI-Immunology™ building block, EvaxMHC, at the 32nd Intelligent Systems for Molecular Biology conference. The advancements in EvaxMHC are expected to enhance Evaxion's ability to accurately predict vaccine targets for personalized and precision vaccines in cancer and infect...
    Stock Region
    Stock Region
    Jun 28 08:55
    Clinical-stage Biotech Company Receives Positive Feedback For AI-based Cancer Vaccine
    Evaxion’s Patent Progress: A Detailed Examination of AI-Based Cancer Vaccine Development.
    Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company, has recently garnered positive feedback on its patent application for a novel AI-based method designed to identify cancer vaccine targets. This advancement represents a pivotal step in the development of personalized cancer treatments, offering the ...
    Trytosaveabit
    Trytosaveabit
    Jun 26 06:39
    Watching closely
    $Evaxion Biotech (EVAX.US)$     Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method.                  Evaxion, On Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method, Says An International Preliminary Report on Patentability Indicates 'Promising Prospects for Obtaining Granted Patents and Protecting the Invention'
Read more

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data